​
​

VectivBio (VECT) Stock Forecast, Price Target & Predictions

OverviewOwnershipChart

VECT Stock Forecast

VectivBio stock forecast is as follows: an average price target of $18.00 (represents a 6.82% upside from VECT’s last price of $16.85) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

VECT Price Target

The average price target for VectivBio (VECT) is $18.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $18.00 to $18.00. This represents a potential 6.82% upside from VECT's last price of $16.85.

VECT Analyst Ratings

Buy

According to 3 Wall Street analysts, VectivBio's rating consensus is 'Buy'. The analyst rating breakdown for VECT stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

VectivBio Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 13, 2022-Jefferies$18.00$8.37115.05%6.82%
Row per page
Go to

The latest VectivBio stock forecast, released on Dec 13, 2022 by Jefferies company, set a price target of $18.00, which represents a 115.05% increase from the stock price at the time of the forecast ($8.37), and a 6.82% increase from VECT last price ($16.85).

VectivBio Price Target by Period

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$16.85$16.85$16.85
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of VectivBio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to VectivBio's last price of $16.85. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Apr 20, 2023Piper SandlerOverweightOverweightHold
Dec 13, 2022Jefferies-BuyInitialise
Sep 30, 2022Piper SandlerOverweightOverweightHold
Jul 01, 2022Piper Sandler-OverweightInitialise
Apr 26, 2022Zacks Investment Research-HoldUpgrade
Row per page
Go to

VectivBio's last stock rating was published by Piper Sandler on Apr 20, 2023. The company gave VECT a "Overweight" rating, the same as its previous rate.

VectivBio Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
HEPAHepion Pharmaceuticals$0.69$70.0010044.93%Buy
ELEVElevation Oncology$0.58$9.001451.72%Buy
CNSPCNS Pharmaceuticals$0.12$0.50316.67%-
IMMXImmix Biopharma$1.82$7.00284.62%Buy
ZURAZura Bio$2.90$10.00244.83%Buy
VECTVectivBio$16.87$18.006.70%Buy
EFTReFFECTOR Therapeutics-$5.50-Buy

VECT Forecast FAQ

Is VectivBio a good buy?

Yes, according to 3 Wall Street analysts, VectivBio (VECT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of VECT's total ratings.

What is VECT's price target?

VectivBio (VECT) average price target is $18 with a range of $18 to $18, implying a 6.82% from its last price of $16.85. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will VectivBio stock go up soon?

According to Wall Street analysts' prediction for VECT stock, the company can go up by 6.82% (from the last price of $16.85 to the average price target of $18), up by 6.82% based on the highest stock price target, and up by 6.82% based on the lowest stock price target.

Can VectivBio stock reach $30?

VECT's average twelve months analyst stock price target of $18 does not support the claim that VectivBio can reach $30 in the near future.